Main Menu

Dr Simon Robinson

Team Leader

The alt text
Dr Simon Robinson is developing non-invasive magnetic resonance imaging (MRI) techniques to assess how tumours respond to treatment. He is internationally recognised for his studies in the use of blood-oxygen-level-dependent MRI in detecting and diagnosing cancer. Team: Magnetic Resonance
020 8722 4528 ORCID 0000-0003-4101-7274


Dr Simon Robinson graduated from City University, London, with a BSc (Hons) degree in Biological Chemistry. During his degree course, he spent an industrial placement year at SmithKline Beecham Pharmaceuticals and was introduced there to the biomedical applications of magnetic resonance imaging (MRI) and spectroscopy.

Subsequently, Dr Robinson successfully pursued a CRC/Zeneca CASE PhD studentship primarily based within the CRC Biomedical Magnetic Resonance Research Group at St George’s, University of London, under the direction of Professors John Griffiths and John Waterton, and secured his PhD in 1995. He continued his postdoctoral studies there, fully exploiting the application of Blood Oxygen Level Dependent (BOLD) MRI in oncology, and for which he gained international recognition.

In October 2001, Dr Robinson was awarded a Royal Society University Research Fellowship. In February 2006, he transferred his Fellowship to The Institute of Cancer Research to take up a Career Development Faculty post to lead a Pre-clinical Imaging Team within the Cancer Research UK Clinical Magnetic Resonance Research Section. This now forms part of the Cancer Research UK & EPSRC Cancer Imaging Centre awarded in 2008, of which Dr Robinson is a Co-Investigator.

Dr Robinson’s research is principally concerned with the application of non-invasive magnetic resonance imaging and spectroscopy (MRI/S) techniques to assess tumours and their response to treatment. The ultimate aim is the identification and development of quantitative MRI/S measurements (biomarkers) of tumours and how they change in response to therapy to assist in the pre-clinical development of new cancer treatments.

Dr Robinson gained the title of Reader at the ICR in 2019.